





Panel Discussion: Solving Loss to Follow-up (in cervical cancer screening in Belgium)

HPV Prevention and Control Board, Antwerp, 28-29/05/2026



Role of BCR: (a) Supporting the Organization and (b) Evaluation of screening programs



Cervical cancer screening in Belgium (25-64 years)

- 2013 – 2024: cytology, 3y intervals
- Opportunistic screening
 - 85% gynaeco; 15% GP
 - FL: organized invitations + fail-safe
 - Screening coverage (2024):
 - 65% of eligible women 25-64 yo
 - 61% (BXL: 58%) of all women 25-64 yo
- Follow-up after cytology (HPV-test)
 - Suboptimal
 - Depending on cyto diagnosis and HPV-result
 - FL: introduction of fail-safe (2018)
→ reminders for GPs
- Since 2025: HPV (30-64), 5y intervals
- **Organized** screening in FL and WAL
 - BXL: remains opportunistic
 - Screening coverage ????
- Follow-up after + screening
 - **triage algorithm**: reflex test + 12m
 - colposcopy /additional FU: ????
 - FL: fail-safe remains

Follow-up results in Flanders (2016 = without fail-safe)


- 90% FU target only reached for most severe diagnoses (ASC-H, AGC, HSIL+ and HPV+)
- Worst results for inadequate samples and ASCUS/LSIL with HPV-
- 2016: 80.2% FU within 12 months
- 2018: introduction fail-safe reminders for GP's
- 2023: 82.3% FU within 12 months
WAL: 77.6% within 12 months; 90% reached after 30 months
BLX: 74.6% within 12 months; 91% reached after 36 months

Denmark: >90% FU after 18 months

Automated reminders
GP-centered



kankerregister.org
registrebredcancer.org



Jørgensen S, et al. J Med Screening 2024; DOI 10.1177/0969146324131440

Annual reports available from <https://baarmpeederhalskanker.be/volkingsonderzoek/be/nl/bhk/literatuur-bhk> (Flanders)
https://kankerregister.org/en/publicaties/rapport/combine-bcombine-op=woordveld_publicatie_domein_target_id=376field_publicatie_jaar_target_id=Allfield_publicatie_kankersort_target_id=Allfield_publicatie_soort_target_id=1748field_publicatie_taal_target_id=All (Wallonia and Brussels)

Panel Discussion: Solving Loss to Follow-up (in cervical cancer screening in Belgium)

Questions / Comments?

Koen Van Herck (MD, PhD)



BCR's role in cancer control

Celebrating 20 years